

0

21 October 2018 | News

The transaction is likely to complete by the end of this year.



Luminex has signed a definitive agreement to buy MilliporeSigma's flow cytometry portfolio for \$75 million.

This deal amount comprises around \$69.9 million to be paid under a stock and asset purchase agreement and around \$5.1million in committed inventory purchases.

The transaction is likely to complete by the end of this year and expected to contribute anywhere between \$40 and \$50 million in revenue to Luminex in 2019.

Luminex will be able to expand its current offering of flow-based detection systems, which is based on its innovative xMAP multiplexing technology. So far, over 15,000 xMAP systems have been sold across the world.